ALLOGENE THERAPEUTICS INC (ALLO) Stock Price, Quote, News and Overview
NASDAQ:ALLO - Nasdaq - US0197701065 - Common Stock - Currency: USD
ALLO Quote, Performance and Key Statistics
1.16
+0.07 (+6.42%)
The current stock price of ALLO is 1.16 USD. In the past month the price decreased by -27.04%. In the past year, price decreased by -53.97%.
ALLO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About ALLO
Company Profile
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 226 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Company Info
ALLOGENE THERAPEUTICS INC
210 East Grand Avenue
South San Francisco CALIFORNIA 94080 US
CEO: David Chang
Employees: 228
Phone: 16504572700
ALLOGENE THERAPEUTICS INC / ALLO FAQ
What is the stock price of ALLOGENE THERAPEUTICS INC today?
The current stock price of ALLO is 1.16 USD. The price increased by 6.42% in the last trading session.
What is the ticker symbol for ALLOGENE THERAPEUTICS INC stock?
The exchange symbol of ALLOGENE THERAPEUTICS INC is ALLO and it is listed on the Nasdaq exchange.
On which exchange is ALLO stock listed?
ALLO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALLOGENE THERAPEUTICS INC stock?
21 analysts have analysed ALLO and the average price target is 9.37 USD. This implies a price increase of 707.37% is expected in the next year compared to the current price of 1.16. Check the ALLOGENE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALLOGENE THERAPEUTICS INC worth?
ALLOGENE THERAPEUTICS INC (ALLO) has a market capitalization of 252.02M USD. This makes ALLO a Micro Cap stock.
How many employees does ALLOGENE THERAPEUTICS INC have?
ALLOGENE THERAPEUTICS INC (ALLO) currently has 228 employees.
What are the support and resistance levels for ALLOGENE THERAPEUTICS INC (ALLO) stock?
ALLOGENE THERAPEUTICS INC (ALLO) has a resistance level at 1.44. Check the full technical report for a detailed analysis of ALLO support and resistance levels.
Is ALLOGENE THERAPEUTICS INC (ALLO) expected to grow?
The Revenue of ALLOGENE THERAPEUTICS INC (ALLO) is expected to decline by -72.68% in the next year. Check the estimates tab for more information on the ALLO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALLOGENE THERAPEUTICS INC (ALLO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALLO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALLO, evaluating the profitability, health, valuation and growth aspects
- ALLOGENE THERAPEUTICS INC (ALLO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALLOGENE THERAPEUTICS INC (ALLO) Sales and EPS estimates to see what analysts future expectations are.
- ALLOGENE THERAPEUTICS INC (ALLO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALLOGENE THERAPEUTICS INC (ALLO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALLOGENE THERAPEUTICS INC (ALLO) Stock Chart to make your own analysis
- ALLOGENE THERAPEUTICS INC (ALLO) Latest news and press-releases to stay up to date.
Does ALLOGENE THERAPEUTICS INC (ALLO) stock pay dividends?
ALLO does not pay a dividend.
When does ALLOGENE THERAPEUTICS INC (ALLO) report earnings?
ALLOGENE THERAPEUTICS INC (ALLO) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of ALLOGENE THERAPEUTICS INC (ALLO)?
ALLOGENE THERAPEUTICS INC (ALLO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.23).
What is the Short Interest ratio of ALLOGENE THERAPEUTICS INC (ALLO) stock?
The outstanding short interest for ALLOGENE THERAPEUTICS INC (ALLO) is 20.18% of its float. Check the ownership tab for more information on the ALLO short interest.
ALLO Technical Analysis
ALLO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALLO. ALLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALLO Financial Highlights
Over the last trailing twelve months ALLO reported a non-GAAP Earnings per Share(EPS) of -1.23. The EPS increased by 28.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.67% | ||
| ROE | -65.47% | ||
| Debt/Equity | 0 |
ALLO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ALLO. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 13.26% and a revenue growth -72.68% for ALLO